Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
316.27
-0.56 (-0.18%)
At close: Nov 12, 2026, 4:00 PM EST
317.00
+0.73 (0.23%)
After-hours: Nov 12, 2026, 7:59 PM EST
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 11 analysts polled by S&P Global, Ligand Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $361.27. The average 1-year stock price forecast is 14.23% higher than the current stock price, while the lowest is $335 (+5.92%) and the highest is $406 (+28.37%).
Price Target: $361.27 (+14.23%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $358 | Buy | Reiterates | $358 | +13.19% | Nov 12, 2026 |
| Barclays | Barclays | Buy Reiterates $345 → $350 | Buy | Reiterates | $345 → $350 | +10.66% | Nov 11, 2026 |
| Citi | Citi | Buy Maintains $397 → $402 | Buy | Maintains | $397 → $402 | +27.11% | Nov 5, 2026 |
Unknown Analyst Leerink Partners No rating | Leerink Partners | Buy Reiterates $330 → $350 | Buy | Reiterates | $330 → $350 | +10.66% | Nov 2, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $357 | Buy | Reiterates | $357 | +12.88% | Nov 2, 2026 |
Financial Forecast
Revenue This Year
291.72M
from 268.09M
Increased by 8.82%
Revenue Next Year
384.11M
from 291.72M
Increased by 31.67%
EPS This Year
9.58
from 8.13
Increased by 17.85%
EPS Next Year
11.95
from 9.58
Increased by 24.77%
EPS and Forward PE are based on non-GAAP adjusted numbers.